Compounds for the treatment of hepatitis C

1. A compound of formula I

R 1 is phenyl where said phenyl is substituted with 1-2 substituents selected from the group consisting of halo, cyano, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (carboxy)alkyl, alkoxy, hydroxyalkyloxy, alkoxyalkyloxy, benzyloxy, tetrahydropyranyloxy, carboxy, alkoxycarbonyl, alkylsulfonyl, (carboxy)alkenyl, (alkoxycarbonyl)alkenyl, alkylcarboxamido, alkoxycarboxamido, alkylsulfamido, (alkylsulfamido)alkyl, Ar 5 , SO 2 NR 15 R 16 , and CONR 7 R 8 ; and where said phenyl is also substituted with 0-2 substituents selected from the group consisting of halo; nitro; alkyl; cycloalkyl; haloalkyl; aminoalkyl; hydroxyalkyl; alkoxyalkyl; hydroxy; alkoxy; OR 17 ; cycloalkoxy; amino; alkylamino; dialkylamino; alkylcarboxamido; alkoxycarboxamido; alkoxyalkylcarboxamido; furanyl, thienyl, or pyrazolyl substituted with 0-2 alkyl substituents; pyridinyl substituted with 0-2 halo, cyano, alkyl, hydroxy, alkoxy, amino, or alkylaminocarbonyl substituents; pyrimidinyl; pyrimidinedionyl; aminopyrimidinyl; indolyl; isoquinolinyl; and phenyl substituted with 0-2 substituents selected from the group consisting of halo, alkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, amino, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarboxamido, carboxyalkenyl, and phenyl;

R 2 is hydrogen, halo, nitro, amino, phenyl, or R 5 R 6 N;

R 3 is cyano, alkoxycarbonyl, (cycloalkyl)oxycarbonyl, (alkylsulfonyl)aminocarbonyl, CONR 11 R 12 , (R 11 )(R 12 )NCONH, triazolyl, thiazolyl, or tetrazolyl;

R 4 is phenyl substituted with 0-2 halo substituents;

R 5 is hydrogen, alkyl, or alkylsulfonyl;

R 6 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or alkylsulfonyl;

R 7 is hydrogen, alkyl, alkenyl, alkynyl, cyanoalkyl, haloalkyl, hydroxyalkyl, dihydroxyalkyl, alkoxyalkyl, oxoalkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkyl)alkyl, cycloalkyl, (alkyl)cycloalkyl, (hydroxyalkyl)cycloalkyl, (tetrahydrofuranyl)alkyl, (tetrahydropyranyl)alkyl, (carboxy)alkyl, (alkoxycarbonyl)alkyl, (alkenyloxycarbonyl)alkyl, (alkoxycarbonyl)hydroxyalkyl, (CONR 13 R 14 )alkyl, (CONR 13 R 14 )(hydroxyalkyl)alkyl, (CONR 13 R 14 )cylcoalkyl, (alkylcarbonyl)aminoalkyl, (phenyl)alkyl, (pyridinyl)alkyl, alkylsulfonyl, phenylsulfonyl, Ar 2 , Ar 3 ,

R 8 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

or R 7 R 8 N taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, dihydroindolyl, or isoindolinyl, and is substituted with 0-2 substituents selected from alkyl, hydroxyalkyl, alkoxyalkyl, hydroxy, alkoxy, carboxy, alkoxycarbonyl, dialkylcarboxamido, alkylcarbonylamino, alkoxycarbonylamino, pyridinyl, and phenyl where said phenyl is substituted with 0-2 halo or alkyl substituents;

or where R 7 R 8 N taken together is

(quinuclidinyl)amino, (quinuclidinyl)(alkyl)amino, (methylpyrrolidinyl)(alkyl)amino, ((imidazolyl)alkyl)(hydroxyalkyl)amino, (alkylthiazolyl)amino, ((carboxamido)cyclopentanyl)amino, ((halophenyl)cyclopentanyl)amino, 3H-spiro(isobenzofuranyl)piperidinyl, (hydroxyindanyl)amino, or

R 9 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

R 10 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl;

or R 9 and R 10 taken together is ethylene, propylene, butylene, pentylene, or hexylene;

R 11 is hydrogen, alkyl, or cycloalkyl;

R 12 is hydrogen, alkyl, or cycloalkyl;

or R 11 and R 12 taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;

R 13 is hydrogen, alkyl, cyanoalkyl, haloalkyl, alkenyl, alkynyl, or thiazolyl;

R 14 is hydrogen or alkyl;

R 15 is hydrogen, alkyl, hydroxyalkyl, cycloalkyl, or benzyl;

R 16 is hydrogen or alkyl;

or R 15 and R 16 taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl;

R 17 is haloalkyl, cyanoalkyl, (cycloalkyl)alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, (R 18 )alkyl, (Ar 4 )alkyl, alkynyl, or aminocycloalkyl;

R 18 is CONH 2 , H 2 NCONH, dibenzylamino, phthalimido, amino, alkylamino, dialkylamino, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl where azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl is substituted with 0-3 alkyl or alkoxycarbonyl substituents;

R 19 is cyano, hydroxyalkyl, morpholinylalkyl, carboxy, alkoxycarbonyl, cycloalkylsulfoxamido, ((alkyl)pyrazolyl)amino, ((alkyl)isoxazolyl)amino, (thiadiazolyl)amino, (triazinyl)amino, or alkynylaminocarbonyl;

R 20 is hydrogen, halo, alkyl, or alkoxy;

R 21 is hydrogen, halo, alkyl, or alkoxy;

Ar 1 is phenyl, naphthalenyl, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, oxadiathiazolyl, triazolyl, tetrazolyl, pyrazinyl, pyrimidinyl, or benzothiazolyl, and is substituted with 0-2 substituents selected from halo, alkyl, cycloalkyl, haloalkyl, alkoxyalkyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, aminocarbonyl, pyridinyl, phenyl, halophenyl, alkylphenyl, and alkoxyphenyl;

Ar 2 is phenyl, biphenyl, or pyridinyl and is substituted with 0-2 substituents selected from halo, alkyl, cyano, hydroxy, alkoxy, and carboxy;

Ar 3 is pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, oxathiadiazolyl, pyrimidinyl, or pyrizinyl and is substituted with 0-2 substituents selected from hydroxy, alkyl, hydroxyalkyl, and CONR 13 R 14 ;

Ar 4 is furanyl, thienyl, pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridinyl, indolyl, or phenyl and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, hydroxyl, and alkoxy; and

Ar 5 is pyrrozolyl, imidazolyl, or oxadiazolyl and is substituted with 0-2 substituents selected from alkyl, carboxy, alkoxycarbonyl, benzyl, and phenyl;

wherein the compound of formula I is selected from the group consisting of

3-benzofurancarboxamide, 4-fluoro-5-[3-fluoro-2-methyl-[[[1-(2-pyrimidinyl)cyclopropyl]amino]carbonyl]phenyl]-2-(4-fluorophenyl)-N-methyl;

3-benzofurancarboxamide, 2-(4-fluorophenyl)-N-methyl-5-[2-methyl-5-[[[1-(2-pyridinyl)cyclopropyl]amino]carbonyl]-4-[(tetrahydro-2H-pyran-4-yl)methoxy]phenyl]-;

3-benzofurancarboxamide, 4-fluoro-2-(4-fluorophenyl)-5-[5-[[[1-(5-fluoro-2-pyrimidinyl)cyclopropyl]amino]carbonyl]-4-methoxy-2-methylphenyl]-N-methyl-;

3-benzofurancarboxamide, 2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[[[1-(5-methyl-2-pyrimidinyl)cyclopropyl]amino]carbonyl]phenyl]-N-methyl-;

3-benzofurancarboxamide, 4-fluoro-2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[[[1-(4-pyrimidinyl)cyclopropyl]amino]carbonyl]phenyl]-N-methyl-;

3-benzofurancarboxamide, 4-fluoro-2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[[[1-(3-pyridazinyl)cyclopropyl]amino]carbonyl]phenyl]-N-methyl-;

3-benzofurancarboxamide, 4-fluoro-2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[[[1-(5-methyl-2-pyrimidinyl)cyclopropyl]amino]carbonyl]phenyl]-N-methyl-;

3-benzofurancarboxamide, 4-fluoro-2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[[[1-(4-methyl-2-pyrimidinyl)cyclopropyl]amino]carbonyl]phenyl]-N-methyl-;

3-benzofurancarboxamide, 4-fluoro-2-(4-fluorophenyl)-N-methyl-5-[2-methyl-5-[[[1-(4-pyrimidinyl)cyclopropyl]amino]carbonyl]phenyl]-;

3-benzofurancarboxamide, 2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[[[1-(5-methyl-4-oxazolyl)cyclopropyl]amino]carbonyl]phenyl]-N-methyl-;

3-benzofurancarboxamide, 2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[[[1-(3-methylphenyl)cyclopropyl]amino]carbonyl]phenyl]-N-methyl-; and

3-benzofurancarboxamide, 2-(4-fluorophenyl)-5-[4-methoxy-2-methyl-5-[[[1-(5-methyl-2-oxazolyl)cyclopropyl]amino]carbonyl]phenyl]-N-methyl-;

or a pharmaceutically acceptable salt thereof.

2. A composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

3. A method of treating hepatitis C infection comprising administering a therapeutically effective amount of a compound of claim 1 to a patient.